trial

Safety and Efficacy of MP-214 in Patients With Schizophrenia

NCTId NCT01625000
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 512 (actual)
Sponsored by Tanabe Pharma Corporation
Primary completion 2015-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
512 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-05
Primary completion
2015-08
Eligibility
ALL · 20 Years · 64 Years

Interventions & indications

Drugs
MP-214 3mgMP-214 6mgMP-214 9mgRisperidone

Sponsors

Tanabe Pharma CorporationLead Sponsor

Sites

0 total

Linked catalysts

1
Safety and Efficacy of MP-214 in Patients With Schizophrenia — primary completion2015-08

Facts & assertions

4 sourced
Enrollment
512
Phase
PHASE2,PHASE3
Primary Completion Date
2015-08
Status
COMPLETED
relationships
The graph out of here
drug
MP-214 3mg
drug
MP-214 6mg
drug
MP-214 9mg
drug
Risperidone
drug
lead_sponsor
Tanabe Pharma Corporation
company
indication
Schizophrenia
indication
Schizophrenia
indication
Mental Disorders
indication